Researchers and clinicians have known that breast cancer is a heterogeneous disease for more than a decade. They've also known that recognized breast cancer subtypes are associated with particular disease outcomes, treatment responses, and mortality rates. What's been more recently contested is whether triple-negative — that is, estrogen receptor-, progesterone receptor-, and HER2-negative — tumors are "effectively the same" as basal-like tumors in terms of disease outcome, according to Paul Pharoah, a senior clinical research fellow at the Cambridge Cancer Centre in the UK.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Helix customers can purchase apps that interpret different aspects of their genome, Technology Review reports.

The New York Times reports that a number of companies and research institutes are pursuing gene therapies.

Salmon with shorter telomeres survive to make the trip back to their river homes, New Scientist reports.

In PLOS this week: vaginal microbiome composition, population patterns of Chagas-carrying Rhodnius ecuadoriensis, and more.